The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CXCR4 Antagonists Market Research Report 2025
Synopsis
CXCR4 antagonists are small-molecule which block the CXCR4 receptors and prevent their activation. Blocking the receptors stop the receptors' ligand, CXCL12, from binding which prevent downstream effects. CXCR4 antagonists are especially important for hindering cancer progression because one of the downstream effects initiated by CXCR4 receptor activation is cell movement which lead to tumor growth and metastasis in cancer patients. The CXCR4 receptor has been targeted by antagonistic substances, these antagonists have prospective use as therapeutic drug agents, and are currently under development in labs worldwide.
The global CXCR4 Antagonists market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for CXCR4 Antagonists is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CXCR4 Antagonists is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for CXCR4 Antagonists in Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of CXCR4 Antagonists include Sanofi, BioLineRx, X4 Pharmaceuticals, Eli Lilly, Roche, Merck, Biokine Therapeutics, GlycoMimetics and Harmonic Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CXCR4 Antagonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CXCR4 Antagonists.
Report Scope
The CXCR4 Antagonists market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CXCR4 Antagonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CXCR4 Antagonists companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
BioLineRx
X4 Pharmaceuticals
Eli Lilly
Roche
Merck
Biokine Therapeutics
GlycoMimetics
Harmonic Pharma
Upsher-Smith Laboratories
Segment by Type
BL-8040
GMI-1359
Plerixafor (AMD3100)
Balixafortide (POL6326)
USL311
Others
Segment by Application
Cancer
HIV
Chronic Inflammatory Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CXCR4 Antagonists companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
CXCR4 antagonists are small-molecule which block the CXCR4 receptors and prevent their activation. Blocking the receptors stop the receptors' ligand, CXCL12, from binding which prevent downstream effects. CXCR4 antagonists are especially important for hindering cancer progression because one of the downstream effects initiated by CXCR4 receptor activation is cell movement which lead to tumor growth and metastasis in cancer patients. The CXCR4 receptor has been targeted by antagonistic substances, these antagonists have prospective use as therapeutic drug agents, and are currently under development in labs worldwide.
The global CXCR4 Antagonists market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for CXCR4 Antagonists is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for CXCR4 Antagonists is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for CXCR4 Antagonists in Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of CXCR4 Antagonists include Sanofi, BioLineRx, X4 Pharmaceuticals, Eli Lilly, Roche, Merck, Biokine Therapeutics, GlycoMimetics and Harmonic Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for CXCR4 Antagonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CXCR4 Antagonists.
Report Scope
The CXCR4 Antagonists market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CXCR4 Antagonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CXCR4 Antagonists companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
BioLineRx
X4 Pharmaceuticals
Eli Lilly
Roche
Merck
Biokine Therapeutics
GlycoMimetics
Harmonic Pharma
Upsher-Smith Laboratories
Segment by Type
BL-8040
GMI-1359
Plerixafor (AMD3100)
Balixafortide (POL6326)
USL311
Others
Segment by Application
Cancer
HIV
Chronic Inflammatory Diseases
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CXCR4 Antagonists companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CXCR4 Antagonists Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 BL-8040
1.2.3 GMI-1359
1.2.4 Plerixafor (AMD3100)
1.2.5 Balixafortide (POL6326)
1.2.6 USL311
1.2.7 Others
1.3 Market by Application
1.3.1 Global CXCR4 Antagonists Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 HIV
1.3.4 Chronic Inflammatory Diseases
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CXCR4 Antagonists Market Perspective (2019-2030)
2.2 CXCR4 Antagonists Growth Trends by Region
2.2.1 Global CXCR4 Antagonists Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 CXCR4 Antagonists Historic Market Size by Region (2019-2024)
2.2.3 CXCR4 Antagonists Forecasted Market Size by Region (2025-2030)
2.3 CXCR4 Antagonists Market Dynamics
2.3.1 CXCR4 Antagonists Industry Trends
2.3.2 CXCR4 Antagonists Market Drivers
2.3.3 CXCR4 Antagonists Market Challenges
2.3.4 CXCR4 Antagonists Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CXCR4 Antagonists Players by Revenue
3.1.1 Global Top CXCR4 Antagonists Players by Revenue (2019-2024)
3.1.2 Global CXCR4 Antagonists Revenue Market Share by Players (2019-2024)
3.2 Global CXCR4 Antagonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CXCR4 Antagonists Revenue
3.4 Global CXCR4 Antagonists Market Concentration Ratio
3.4.1 Global CXCR4 Antagonists Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CXCR4 Antagonists Revenue in 2023
3.5 CXCR4 Antagonists Key Players Head office and Area Served
3.6 Key Players CXCR4 Antagonists Product Solution and Service
3.7 Date of Enter into CXCR4 Antagonists Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CXCR4 Antagonists Breakdown Data by Type
4.1 Global CXCR4 Antagonists Historic Market Size by Type (2019-2024)
4.2 Global CXCR4 Antagonists Forecasted Market Size by Type (2025-2030)
5 CXCR4 Antagonists Breakdown Data by Application
5.1 Global CXCR4 Antagonists Historic Market Size by Application (2019-2024)
5.2 Global CXCR4 Antagonists Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America CXCR4 Antagonists Market Size (2019-2030)
6.2 North America CXCR4 Antagonists Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America CXCR4 Antagonists Market Size by Country (2019-2024)
6.4 North America CXCR4 Antagonists Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CXCR4 Antagonists Market Size (2019-2030)
7.2 Europe CXCR4 Antagonists Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe CXCR4 Antagonists Market Size by Country (2019-2024)
7.4 Europe CXCR4 Antagonists Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CXCR4 Antagonists Market Size (2019-2030)
8.2 Asia-Pacific CXCR4 Antagonists Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific CXCR4 Antagonists Market Size by Region (2019-2024)
8.4 Asia-Pacific CXCR4 Antagonists Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CXCR4 Antagonists Market Size (2019-2030)
9.2 Latin America CXCR4 Antagonists Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America CXCR4 Antagonists Market Size by Country (2019-2024)
9.4 Latin America CXCR4 Antagonists Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CXCR4 Antagonists Market Size (2019-2030)
10.2 Middle East & Africa CXCR4 Antagonists Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa CXCR4 Antagonists Market Size by Country (2019-2024)
10.4 Middle East & Africa CXCR4 Antagonists Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi CXCR4 Antagonists Introduction
11.1.4 Sanofi Revenue in CXCR4 Antagonists Business (2019-2024)
11.1.5 Sanofi Recent Development
11.2 BioLineRx
11.2.1 BioLineRx Company Detail
11.2.2 BioLineRx Business Overview
11.2.3 BioLineRx CXCR4 Antagonists Introduction
11.2.4 BioLineRx Revenue in CXCR4 Antagonists Business (2019-2024)
11.2.5 BioLineRx Recent Development
11.3 X4 Pharmaceuticals
11.3.1 X4 Pharmaceuticals Company Detail
11.3.2 X4 Pharmaceuticals Business Overview
11.3.3 X4 Pharmaceuticals CXCR4 Antagonists Introduction
11.3.4 X4 Pharmaceuticals Revenue in CXCR4 Antagonists Business (2019-2024)
11.3.5 X4 Pharmaceuticals Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly CXCR4 Antagonists Introduction
11.4.4 Eli Lilly Revenue in CXCR4 Antagonists Business (2019-2024)
11.4.5 Eli Lilly Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche CXCR4 Antagonists Introduction
11.5.4 Roche Revenue in CXCR4 Antagonists Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck CXCR4 Antagonists Introduction
11.6.4 Merck Revenue in CXCR4 Antagonists Business (2019-2024)
11.6.5 Merck Recent Development
11.7 Biokine Therapeutics
11.7.1 Biokine Therapeutics Company Detail
11.7.2 Biokine Therapeutics Business Overview
11.7.3 Biokine Therapeutics CXCR4 Antagonists Introduction
11.7.4 Biokine Therapeutics Revenue in CXCR4 Antagonists Business (2019-2024)
11.7.5 Biokine Therapeutics Recent Development
11.8 GlycoMimetics
11.8.1 GlycoMimetics Company Detail
11.8.2 GlycoMimetics Business Overview
11.8.3 GlycoMimetics CXCR4 Antagonists Introduction
11.8.4 GlycoMimetics Revenue in CXCR4 Antagonists Business (2019-2024)
11.8.5 GlycoMimetics Recent Development
11.9 Harmonic Pharma
11.9.1 Harmonic Pharma Company Detail
11.9.2 Harmonic Pharma Business Overview
11.9.3 Harmonic Pharma CXCR4 Antagonists Introduction
11.9.4 Harmonic Pharma Revenue in CXCR4 Antagonists Business (2019-2024)
11.9.5 Harmonic Pharma Recent Development
11.10 Upsher-Smith Laboratories
11.10.1 Upsher-Smith Laboratories Company Detail
11.10.2 Upsher-Smith Laboratories Business Overview
11.10.3 Upsher-Smith Laboratories CXCR4 Antagonists Introduction
11.10.4 Upsher-Smith Laboratories Revenue in CXCR4 Antagonists Business (2019-2024)
11.10.5 Upsher-Smith Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global CXCR4 Antagonists Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of BL-8040
Table 3. Key Players of GMI-1359
Table 4. Key Players of Plerixafor (AMD3100)
Table 5. Key Players of Balixafortide (POL6326)
Table 6. Key Players of USL311
Table 7. Key Players of Others
Table 8. Global CXCR4 Antagonists Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global CXCR4 Antagonists Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global CXCR4 Antagonists Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global CXCR4 Antagonists Market Share by Region (2019-2024)
Table 12. Global CXCR4 Antagonists Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global CXCR4 Antagonists Market Share by Region (2025-2030)
Table 14. CXCR4 Antagonists Market Trends
Table 15. CXCR4 Antagonists Market Drivers
Table 16. CXCR4 Antagonists Market Challenges
Table 17. CXCR4 Antagonists Market Restraints
Table 18. Global CXCR4 Antagonists Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global CXCR4 Antagonists Market Share by Players (2019-2024)
Table 20. Global Top CXCR4 Antagonists Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CXCR4 Antagonists as of 2023)
Table 21. Ranking of Global Top CXCR4 Antagonists Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by CXCR4 Antagonists Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players CXCR4 Antagonists Product Solution and Service
Table 25. Date of Enter into CXCR4 Antagonists Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global CXCR4 Antagonists Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global CXCR4 Antagonists Revenue Market Share by Type (2019-2024)
Table 29. Global CXCR4 Antagonists Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global CXCR4 Antagonists Revenue Market Share by Type (2025-2030)
Table 31. Global CXCR4 Antagonists Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global CXCR4 Antagonists Revenue Market Share by Application (2019-2024)
Table 33. Global CXCR4 Antagonists Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global CXCR4 Antagonists Revenue Market Share by Application (2025-2030)
Table 35. North America CXCR4 Antagonists Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America CXCR4 Antagonists Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America CXCR4 Antagonists Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe CXCR4 Antagonists Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe CXCR4 Antagonists Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe CXCR4 Antagonists Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific CXCR4 Antagonists Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific CXCR4 Antagonists Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific CXCR4 Antagonists Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America CXCR4 Antagonists Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America CXCR4 Antagonists Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America CXCR4 Antagonists Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa CXCR4 Antagonists Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa CXCR4 Antagonists Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa CXCR4 Antagonists Market Size by Country (2025-2030) & (US$ Million)
Table 50. Sanofi Company Detail
Table 51. Sanofi Business Overview
Table 52. Sanofi CXCR4 Antagonists Product
Table 53. Sanofi Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 54. Sanofi Recent Development
Table 55. BioLineRx Company Detail
Table 56. BioLineRx Business Overview
Table 57. BioLineRx CXCR4 Antagonists Product
Table 58. BioLineRx Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 59. BioLineRx Recent Development
Table 60. X4 Pharmaceuticals Company Detail
Table 61. X4 Pharmaceuticals Business Overview
Table 62. X4 Pharmaceuticals CXCR4 Antagonists Product
Table 63. X4 Pharmaceuticals Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 64. X4 Pharmaceuticals Recent Development
Table 65. Eli Lilly Company Detail
Table 66. Eli Lilly Business Overview
Table 67. Eli Lilly CXCR4 Antagonists Product
Table 68. Eli Lilly Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 69. Eli Lilly Recent Development
Table 70. Roche Company Detail
Table 71. Roche Business Overview
Table 72. Roche CXCR4 Antagonists Product
Table 73. Roche Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 74. Roche Recent Development
Table 75. Merck Company Detail
Table 76. Merck Business Overview
Table 77. Merck CXCR4 Antagonists Product
Table 78. Merck Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 79. Merck Recent Development
Table 80. Biokine Therapeutics Company Detail
Table 81. Biokine Therapeutics Business Overview
Table 82. Biokine Therapeutics CXCR4 Antagonists Product
Table 83. Biokine Therapeutics Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 84. Biokine Therapeutics Recent Development
Table 85. GlycoMimetics Company Detail
Table 86. GlycoMimetics Business Overview
Table 87. GlycoMimetics CXCR4 Antagonists Product
Table 88. GlycoMimetics Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 89. GlycoMimetics Recent Development
Table 90. Harmonic Pharma Company Detail
Table 91. Harmonic Pharma Business Overview
Table 92. Harmonic Pharma CXCR4 Antagonists Product
Table 93. Harmonic Pharma Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 94. Harmonic Pharma Recent Development
Table 95. Upsher-Smith Laboratories Company Detail
Table 96. Upsher-Smith Laboratories Business Overview
Table 97. Upsher-Smith Laboratories CXCR4 Antagonists Product
Table 98. Upsher-Smith Laboratories Revenue in CXCR4 Antagonists Business (2019-2024) & (US$ Million)
Table 99. Upsher-Smith Laboratories Recent Development
Table 100. Research Programs/Design for This Report
Table 101. Key Data Information from Secondary Sources
Table 102. Key Data Information from Primary Sources
List of Figures
Figure 1. Global CXCR4 Antagonists Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global CXCR4 Antagonists Market Share by Type: 2023 VS 2030
Figure 3. BL-8040 Features
Figure 4. GMI-1359 Features
Figure 5. Plerixafor (AMD3100) Features
Figure 6. Balixafortide (POL6326) Features
Figure 7. USL311 Features
Figure 8. Others Features
Figure 9. Global CXCR4 Antagonists Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global CXCR4 Antagonists Market Share by Application: 2023 VS 2030
Figure 11. Cancer Case Studies
Figure 12. HIV Case Studies
Figure 13. Chronic Inflammatory Diseases Case Studies
Figure 14. CXCR4 Antagonists Report Years Considered
Figure 15. Global CXCR4 Antagonists Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global CXCR4 Antagonists Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global CXCR4 Antagonists Market Share by Region: 2023 VS 2030
Figure 18. Global CXCR4 Antagonists Market Share by Players in 2023
Figure 19. Global Top CXCR4 Antagonists Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CXCR4 Antagonists as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by CXCR4 Antagonists Revenue in 2023
Figure 21. North America CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America CXCR4 Antagonists Market Share by Country (2019-2030)
Figure 23. United States CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe CXCR4 Antagonists Market Share by Country (2019-2030)
Figure 27. Germany CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific CXCR4 Antagonists Market Share by Region (2019-2030)
Figure 35. China CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America CXCR4 Antagonists Market Share by Country (2019-2030)
Figure 43. Mexico CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa CXCR4 Antagonists Market Share by Country (2019-2030)
Figure 47. Turkey CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia CXCR4 Antagonists Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Sanofi Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 50. BioLineRx Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 51. X4 Pharmaceuticals Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 52. Eli Lilly Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 53. Roche Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 54. Merck Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 55. Biokine Therapeutics Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 56. GlycoMimetics Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 57. Harmonic Pharma Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 58. Upsher-Smith Laboratories Revenue Growth Rate in CXCR4 Antagonists Business (2019-2024)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
